bevacizumab + capecitabine + levocetirizine

This is a combination therapy consisting of bevacizumab (an anti-angiogenic monoclonal antibody), capecitabine (a chemotherapy drug), and levocetirizine (an antihistamine). The combination was studied in a phase II clinical trial for patients with refractory metastatic colorectal cancer (mCRC). The rationale behind this combination is that levocetirizine, which has anti-inflammatory and IL-8 suppression properties, may help overcome resistance to anti-angiogenic therapy (bevacizumab). Capecitabine works by disrupting DNA and RNA synthesis in cancer cells, while bevacizumab blocks tumor angiogenesis by inhibiting vascular endothelial growth factor (VEGF).

Other names

Levocetirizine with Capecitabine and BevacizumabCapecitabine, Bevacizumab, and Levocetirizine Regimen